IndieBio

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

Ten63 Therapeutics is a biotechnology company focused on developing innovative therapeutics for challenging diseases, particularly those involving targets previously considered undruggable. Founded in 2017 and based in Chapel Hill, North Carolina, the company utilizes its proprietary platform, COPPER, which integrates advanced artificial intelligence and state-of-the-art physical models to explore vast chemical spaces. By employing low-residual, machine learning-based computational chemistry alongside superlinear search algorithms, Ten63 Therapeutics aims to identify and optimize drug candidates effectively. Their approach includes proprietary scaffold redesign and hopping technology, enabling the screening of trillions of molecules to predict resistance and redesign antibodies. This combination of techniques positions Ten63 Therapeutics at the forefront of developing durable treatments for some of the most lethal diseases.

BioLattice is a biotechnology company focused on developing tissue-engineered cornea technology. Their primary goal is to provide a viable alternative to donor tissue for full-thickness corneal transplants. The company's innovative technology offers a corneal prototype with vision-correcting capabilities, aiming to restore sight for patients requiring corneal transplants.

Vitarka Therapeutics is a London-based company focused on developing medical technologies and solutions for various types of cancer. The company has created a targeted non-viral delivery platform aimed at intracellular targets in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage patients suffering from lung, colon, breast, and other cancers. By utilizing re-engineered pore-forming proteins for cell-specific targeting and facilitating the endosomal release of therapeutic cargo, Vitarka Therapeutics aims to provide cancer patients with renewed hope and the potential to lead more normal lives.

VIAN Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop intended to replace traditional injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical trials, VIAN aims to meet significant unmet medical needs in the retinal disease market, which is valued at $15 billion. Additionally, the company is engaged in the creation of peptide drugs that enhance efficacy and safety for treating both ophthalmic and oncology-related conditions by targeting angiogenesis, thereby offering patients improved health outcomes.

Laguna Bio is a biotechnology company based in Berkeley, California, founded in 2022. The company focuses on drug discovery, specifically developing a platform that activates and expands the innate immune system to combat cancer. Laguna Bio specializes in enhancing a specific type of T cell that targets solid tumors, aiming to improve the efficacy of bispecific antibody drugs. By increasing the immune response against these tumors, the company seeks to provide innovative solutions that may help patients survive cancer more effectively.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

DisperseBio is a Biotechnology Research firm developing a mechanism to counter microbial contamination on natural surfaces like human body.

Metabolic Psychiatry Labs is a mental healthcare company that provides remote treatment solutions for mental illnesses. Their platform integrates metabolic and mental health research, data tracking, metabolic interventions, and personalized medical care, enabling patients to receive effective treatments from home. The company offers assessments, lab tests, and wellness solutions based on metabolic therapy.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Minutia is focused on developing innovative solutions for Type 1 Diabetes through stem cell-derived transplants that incorporate nanosensors. The company specializes in creating subcutaneous insulin-producing cell transplants that are immune-evasive and capable of real-time monitoring via proprietary cell-based sensors. This approach aims to address common challenges associated with transplants and seeks to provide a functional cure for diabetes. By advancing both transplantation techniques and monitoring capabilities, Minutia aspires to transform the clinical landscape of diabetes management and cell replacement therapies.

Calyx develops advanced sensor platforms that monitor various parameters in poultry and livestock, utilizing cutting-edge technology to address complex challenges in the industry. The company specializes in gas sensor technology that detects airborne chemical emissions through innovative sensors patterned with viruses that bind to specific gas molecules. These sensors provide high specificity and sensitivity, changing color in response to different gases and their concentrations. By integrating artificial intelligence, computer vision technology, and data science, Calyx aims to enhance environmental monitoring and improve health outcomes for livestock and poultry, offering commercial customers effective solutions to track daily environmental changes.

Asta Bio is a biotechnology company specializing in the development of radiotherapeutics for cancer treatment. It focuses on combining the alpha-emitting radioisotope 211-Astatine with multivalent single-domain antibodies to deliver targeted alpha radiation to tumor cells, sparing healthy cells. This approach aims to effectively destroy cancer cells by breaking their DNA strands.

Tinkeso Therapeutics is a biotechnology company specializing in the development of innovative cell therapies for treating cancer and autoimmune diseases. The company focuses on creating off-the-shelf, allogeneic chimeric antigen receptor (CAR) engineered natural killer T (NKT) cell therapies. These therapies use NKT cells to target and destroy cancer cells or modulate the immune response in autoimmune conditions, aiming to increase treatment accessibility and scalability.

heXem bio specializes in recording solutions for the early development of humans for longevity.

OncoPrecision is a company that focuses on improving cancer therapy outcomes by utilizing a patient micro avatar platform. This innovative platform employs single-cell high-throughput biology and machine learning to generate comprehensive patient-derived phenotypic biomarkers. By doing so, it enables oncologists to make informed, data-driven decisions regarding the selection of cancer therapies tailored to individual patients. The approach aims to increase the success rates of cancer treatments by ensuring that the right therapy is matched to the right patient, thus enhancing overall patient care and treatment effectiveness.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Calder Biosciences is focused on developing next-generation vaccines to address significant public health challenges posed by evolving viruses. Their innovative 3D-Vaxlock technology enhances vaccine stability and efficacy by creating molecular structures that maintain the most effective shapes of immunogens. This approach aims to improve protection against respiratory syncytial virus (RSV), particularly for the elderly, and to create a universal flu vaccine effective against all seasonal strains. By addressing the limitations of traditional vaccine designs, Calder aims to deliver solutions that provide better safety, durability, and effectiveness for at-risk populations. Ultimately, their goal is to prevent severe illnesses and reduce the healthcare burden, contributing to healthier lives for billions of people.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to detect and eliminate cancer from within the body. The company is dedicated to advancing scientific breakthroughs that lead to new classes of treatments, providing significant improvements in medicine. RyboDyn's work is particularly concentrated on creating upgraded therapies for serious diseases, including terminal conditions, with the goal of enhancing patient outcomes and expanding treatment options.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Hypercell Technologies focuses on developing innovative diagnostic tools and monoclonal antibodies aimed at controlling infectious diseases in animals. The company employs molecular biology techniques to create accurate in-farm diagnostic tools that deliver results in under one hour. This rapid testing capability, combined with their antibodies, allows veterinarians to effectively manage and mitigate the spread of viruses within production animal populations. Hypercell Technologies is committed to preventing potential pandemics in humans by addressing the root causes of infectious diseases in animal reservoirs.

Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Calder Biosciences is focused on developing next-generation vaccines to address significant public health challenges posed by evolving viruses. Their innovative 3D-Vaxlock technology enhances vaccine stability and efficacy by creating molecular structures that maintain the most effective shapes of immunogens. This approach aims to improve protection against respiratory syncytial virus (RSV), particularly for the elderly, and to create a universal flu vaccine effective against all seasonal strains. By addressing the limitations of traditional vaccine designs, Calder aims to deliver solutions that provide better safety, durability, and effectiveness for at-risk populations. Ultimately, their goal is to prevent severe illnesses and reduce the healthcare burden, contributing to healthier lives for billions of people.

Xias Bio is a biotechnology startup focused on producing recombinant proteins that enhance the delivery of functional ingredients for various sectors, including research, beauty, and healthcare. The company specializes in developing non-immunogenic natural motifs, which provide a superior platform for creating soluble and active ingredients with desirable properties such as improved gel and film formation and antioxidant effects. By offering an adaptable, animal product-free biomaterial, Xias Bio delivers tailored biological functionalities that outperform traditional synthetic and animal-based products. This innovation enables pharmaceutical and cosmetic companies to access non-toxic, non-immunogenic alternatives for a wide range of applications.

QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies for the treatment of various human diseases, with a particular focus on oncology. The company has created a blood stem cell-derived epigenetic platform designed to address challenges related to donor source availability, cellular potency, and the complexities of manufacturing clinical-grade cell products. By leveraging this innovative platform, Cell BioEngines aims to produce cell-based therapies that can provide long-lasting benefits to patients, ultimately striving to transform cancer into a curable disease.

TippingPoint Biosciences is focused on developing therapeutics that address diseases linked to defects in DNA packaging, including various cancers and neurodegenerative disorders. Utilizing a drug discovery platform, the company aims to identify innovative treatments that specifically target unique genome packaging states associated with these diseases. This approach not only facilitates the treatment of cancers but also supports the development of stem cell therapies by addressing the underlying issues of dysfunctional genome packaging. Through its efforts, TippingPoint Biosciences seeks to advance medical care and improve patient outcomes in complex genetic conditions.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

Kresko RNAtech is a biotechnology company focused on the development and production of nutraceuticals. The company specializes in identifying bioactive ribonucleic acid (RNA) from natural sources, utilizing advanced techniques such as machine learning and bioinformatics. By uncovering RNAs that may offer health benefits, Kresko RNAtech aims to enhance human well-being and help individuals manage stressful and changing conditions through innovative RNA technologies.

Geltor, Inc. is a biodesign company based in San Leandro, California, that specializes in producing bioactive, animal-free collagens and proteins for various applications in beauty, nutrition, and wellness. Established in 2015, Geltor offers innovative products such as Collume, which promotes skincare cellular regeneration and dermal synthesis, and HumaColl21, which enhances skin health by boosting collagen and elastin levels. Additionally, the company provides vegan collagen peptides and other novel proteins designed for functional food and nutraceutical formulations. Geltor's products are sustainably cultivated and clinically validated, allowing businesses to create effective, plant-based solutions that contribute to a more sustainable future.

Vitarka Therapeutics is a London-based company focused on developing medical technologies and solutions for various types of cancer. The company has created a targeted non-viral delivery platform aimed at intracellular targets in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage patients suffering from lung, colon, breast, and other cancers. By utilizing re-engineered pore-forming proteins for cell-specific targeting and facilitating the endosomal release of therapeutic cargo, Vitarka Therapeutics aims to provide cancer patients with renewed hope and the potential to lead more normal lives.

Beeflow S.A., founded in 2016 and based in Buenos Aires, Argentina, specializes in providing professional pollination services to farmers. The company leverages scientific knowledge and technology to enhance bee populations, developing organic compounds that improve the immune systems of bees and guide them to pollinate specific crops. This approach not only helps increase crop yields—reported to be between 20-90% for various fruits such as blueberries, almonds, raspberries, and kiwifruit—but also addresses the decline in bee populations. By focusing on the health and efficiency of bees, Beeflow aims to maintain the security of plant ecosystems and support sustainable agriculture practices.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

FluoSphera is a company focused on the development of innovative drugs that minimize adverse side effects and reduce reliance on animal testing. By addressing the complexities of human physiological responses, FluoSphera aims to assist organizations in creating safer pharmaceuticals and protecting populations from harmful compounds. Their approach emphasizes efficiency in drug discovery, ultimately enhancing public health and safety.

Mimio Health is a nutraceutical company dedicated to the research and production of mimetic supplements. Its innovative fasting mimetic formulation is based on clinical research and utilizes a carefully selected combination of bioactive human metabolites. This formulation aims to replicate the body’s natural response to fasting, offering the potential health benefits of fasting without the need to undergo the fasting process. Mimio's products focus on promoting cellular health, providing anti-inflammatory and antioxidant effects that may help combat age-related chronic inflammation and cellular damage.

Aluna, established in 2013 and headquartered in San Francisco, specializes in developing medical devices and digital health platforms for managing chronic respiratory conditions, primarily asthma. The company's core product is a portable spirometry device that connects with an interactive iPhone game, enabling users, especially children, to track and monitor their asthma symptoms, medication, and potential triggers in real-time. This data is shared with healthcare providers, facilitating personalized treatment plans and early intervention. Aluna's mission is to empower patients to understand and manage their lung health, improving overall asthma outcomes.

AvantGuard creats innovative solutions that manage surfaces and provide long-term protection against viruses, bacteria, and fungi/mold, in a variety of applications.

BioROSA Technologies Inc. is a Belmont, Massachusetts-based company focused on developing blood tests for Autism Spectrum Disorders (ASD). Founded in 2018, the company aims to establish a biologically-based standard of care for ASD through innovative diagnostic tools. These tools enable clinicians to identify individuals at risk for ASD by utilizing blood-based biomarkers and advanced machine learning techniques. BioROSA’s platform not only enhances early detection and diagnosis but also supports therapeutic developments by facilitating patient stratification and assessing pharmacodynamics in clinical trials. This comprehensive approach equips healthcare professionals with the necessary resources to improve patient outcomes through timely intervention.

FluoSphera is a company focused on the development of innovative drugs that minimize adverse side effects and reduce reliance on animal testing. By addressing the complexities of human physiological responses, FluoSphera aims to assist organizations in creating safer pharmaceuticals and protecting populations from harmful compounds. Their approach emphasizes efficiency in drug discovery, ultimately enhancing public health and safety.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Harmony is a biotechnology startup that creates human breast milk protein-based infant nutrition designed to help human babies thrive. It is the world’s first dairy-free, allergen-free and environmentally friendly infant nutrition. Harmony Baby Nutrition was established in 2018 and is based in Boston, MA.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Vitarka Therapeutics is a London-based company focused on developing medical technologies and solutions for various types of cancer. The company has created a targeted non-viral delivery platform aimed at intracellular targets in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage patients suffering from lung, colon, breast, and other cancers. By utilizing re-engineered pore-forming proteins for cell-specific targeting and facilitating the endosomal release of therapeutic cargo, Vitarka Therapeutics aims to provide cancer patients with renewed hope and the potential to lead more normal lives.

Wayfinder Biosciences is a biotechnology company based in Seattle, WA, focused on developing orally available small molecule drugs that target RNA to address key disease areas such as oncology and neurodegenerative disorders. Established in 2021, the company employs a proprietary platform that integrates advanced screening technologies and computational methods to efficiently discover potent and selective RNA-targeting molecules. By leveraging high-throughput screening combined with machine learning and unique datasets, Wayfinder aims to enable the development of drugs for traditionally inaccessible targets, thus addressing significant unmet medical needs in genetic diseases, cancer, and other conditions.

Aima, founded in 2019 and based in Vancouver, Canada, focuses on transforming menstrual pain management. The company provides a proactive weekly pain management system tailored for menstruators, offering personalized and effective medications. Aima aims to empower users to manage their period pain with a sense of freedom and dignity, enhancing their overall quality of life.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Laguna Bio is a biotechnology company based in Berkeley, California, founded in 2022. The company focuses on drug discovery, specifically developing a platform that activates and expands the innate immune system to combat cancer. Laguna Bio specializes in enhancing a specific type of T cell that targets solid tumors, aiming to improve the efficacy of bispecific antibody drugs. By increasing the immune response against these tumors, the company seeks to provide innovative solutions that may help patients survive cancer more effectively.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Ria Health is an online platform that provides telehealth services for individuals looking to improve their relationship with alcohol. It offers personalized treatment plans that include medication-assisted treatment options and behavioral therapies, all supported by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability in their recovery journey. Ria Health features a mobile app that grants users access to educational materials, support groups, and direct communication with care teams. This comprehensive approach aims to assist individuals in managing alcohol consumption and fostering healthier habits.

BioLumen is a nutritional technology company that develops a patented dietary fiber technology platform that reduces the negative effect of a diet heavy in processed foods. BioLumen's technology is composed of insoluble dietary fiber matrix covered with a blend of food ingredients created from the latest drug delivery system research. The company's product, a nutraceutical, focuses on high risk individuals with prediabetes to help manage blood sugar levels, protect their liver from excess sugar and feed their gut microbiome, delivering health benefits. BioLumen was founded on 2018 and is headquartered in San Francisco, California.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

Kalia Health is a biotechnology company based in Chapel Hill, North Carolina, that focuses on enhancing maternal health outcomes. Founded in 2019, the company has developed a home-based early detection test specifically aimed at identifying preeclampsia, a potentially severe pregnancy complication. Their product includes a low-cost and reliable detection strip that allows mothers to self-screen for preeclampsia periodically. This innovation is designed to improve accessibility to early diagnosis, enabling women to seek timely medical care and mitigate the risks associated with this condition. Kalia Health's commitment to safe and affordable maternal health solutions positions it as a valuable contributor to improving health outcomes for expectant mothers.

Tesarakt is a New York City-based company founded in 2022 that specializes in predictive artificial intelligence for brain care. The firm focuses on developing AI technology aimed at predicting neurological disorders prior to disease progression. By leveraging artificial intelligence and machine learning, Tesarakt enhances the predictive capabilities of neuro-diagnosis through an extensive database of conventional MRI scans. This innovative approach enables medical professionals to identify conditions such as Parkinson's disease and Alzheimer's disease before the onset of initial symptoms, thereby improving early intervention and patient outcomes.

Tesarakt is a New York City-based company founded in 2022 that specializes in predictive artificial intelligence for brain care. The firm focuses on developing AI technology aimed at predicting neurological disorders prior to disease progression. By leveraging artificial intelligence and machine learning, Tesarakt enhances the predictive capabilities of neuro-diagnosis through an extensive database of conventional MRI scans. This innovative approach enables medical professionals to identify conditions such as Parkinson's disease and Alzheimer's disease before the onset of initial symptoms, thereby improving early intervention and patient outcomes.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Kalia Health is a biotechnology company based in Chapel Hill, North Carolina, that focuses on enhancing maternal health outcomes. Founded in 2019, the company has developed a home-based early detection test specifically aimed at identifying preeclampsia, a potentially severe pregnancy complication. Their product includes a low-cost and reliable detection strip that allows mothers to self-screen for preeclampsia periodically. This innovation is designed to improve accessibility to early diagnosis, enabling women to seek timely medical care and mitigate the risks associated with this condition. Kalia Health's commitment to safe and affordable maternal health solutions positions it as a valuable contributor to improving health outcomes for expectant mothers.

Proteinea is a biotechnology company that specializes in developing biotherapeutics by utilizing advanced protein engineering techniques. The company has created a platform that employs proprietary artificial intelligence models and computational tools to design next-generation antibodies with enhanced efficacy, safety, and convenience. By integrating novel deep-learning models with smart experimental throughput, Proteinea aims to streamline the process of biologics design for antibody medicines. This innovative approach allows clients to evaluate the efficacy, yield, safety, and pharmacological properties of their products more effectively, ultimately leading to smarter and faster development of therapeutic solutions.

QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

ArgenTag is a biotech startup focused on democratizing genomic sequencing through innovative technology. The company has developed a robust solution that significantly reduces the costs associated with long-read sequencing applications. By integrating micro-fabrication, next-generation DNA sequencing, molecular biology, and mechanical engineering, ArgenTag's platform produces synthetic DNA barcodes, allowing for the simultaneous sequencing of thousands of samples. This technology enables medical professionals to analyze antibodies and perform single-cell sequencing, making advanced genomic analysis more accessible to a broader audience.

ArgenTag is a biotech startup focused on democratizing genomic sequencing through innovative technology. The company has developed a robust solution that significantly reduces the costs associated with long-read sequencing applications. By integrating micro-fabrication, next-generation DNA sequencing, molecular biology, and mechanical engineering, ArgenTag's platform produces synthetic DNA barcodes, allowing for the simultaneous sequencing of thousands of samples. This technology enables medical professionals to analyze antibodies and perform single-cell sequencing, making advanced genomic analysis more accessible to a broader audience.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Cellens is a medical device company based in Medford, Massachusetts, that specializes in noninvasive cancer screening, particularly for bladder cancer. Founded in 2019 as a spinoff from Tufts University, the company has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning. This innovative platform analyzes physio-biomarkers on cell surfaces obtained from urine samples, generating a diagnostics score for bladder cancer. By providing oncologists and urologists with a reliable and less invasive alternative to traditional diagnostic methods, Cellens aims to enhance patient outcomes and reduce the need for costly and invasive procedures.

Cellens is a medical device company based in Medford, Massachusetts, that specializes in noninvasive cancer screening, particularly for bladder cancer. Founded in 2019 as a spinoff from Tufts University, the company has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning. This innovative platform analyzes physio-biomarkers on cell surfaces obtained from urine samples, generating a diagnostics score for bladder cancer. By providing oncologists and urologists with a reliable and less invasive alternative to traditional diagnostic methods, Cellens aims to enhance patient outcomes and reduce the need for costly and invasive procedures.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Grand Bio is working to improve the efficiency with which cells create their own growth factors. The firm provides supplements that boost growth factors in the medium in which cells live and thrive.

Grand Bio is working to improve the efficiency with which cells create their own growth factors. The firm provides supplements that boost growth factors in the medium in which cells live and thrive.

Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can inhibit or promote ferroptosis, a form of regulated cell death. By targeting this process, Prothegen seeks to provide effective therapeutic options for patients, enhancing the treatment of conditions associated with uncontrolled cell death.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can inhibit or promote ferroptosis, a form of regulated cell death. By targeting this process, Prothegen seeks to provide effective therapeutic options for patients, enhancing the treatment of conditions associated with uncontrolled cell death.

OncoPrecision is a company that focuses on improving cancer therapy outcomes by utilizing a patient micro avatar platform. This innovative platform employs single-cell high-throughput biology and machine learning to generate comprehensive patient-derived phenotypic biomarkers. By doing so, it enables oncologists to make informed, data-driven decisions regarding the selection of cancer therapies tailored to individual patients. The approach aims to increase the success rates of cancer treatments by ensuring that the right therapy is matched to the right patient, thus enhancing overall patient care and treatment effectiveness.

Indee Labs specializes in developing innovative hardware for gene delivery, focusing on a non-viral intracellular delivery system. This technology facilitates the efficient development and scalable manufacture of gene-modified cell therapies, including chimeric antigen receptor T cells. By employing microfluidic vortex shedding, the system enables the gentle delivery of constructs such as nucleic acids, proteins, and gene-editing complexes to a variety of cell types, ensuring maximum recovery of viable, modified cells with minimal disruption. Indee Labs collaborates with the Australian National Fabrication Facility and has established its presence with offices in Sydney and lab space at Bonneville Labs in Berkeley. The company is recognized for its contributions to the field, having affiliations with NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.

Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.

Kutanios is a biotechnology company based in London that specializes in the development of innovative compounds for various skincare applications, including anti-aging, sun protection, and anti-acne treatments. The firm focuses on creating biodegradable molecules that utilize a novel mechanism of action, which targets lipid peroxides generated by environmental factors such as sunlight, pollution, and tobacco smoke. By employing green technology in the manufacturing process, Kutanios aims to provide effective solutions that help prevent skin aging, sunburn, and skin cancers, catering to the needs of consumers seeking safer and more effective skincare options.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

Beeflow S.A., founded in 2016 and based in Buenos Aires, Argentina, specializes in providing professional pollination services to farmers. The company leverages scientific knowledge and technology to enhance bee populations, developing organic compounds that improve the immune systems of bees and guide them to pollinate specific crops. This approach not only helps increase crop yields—reported to be between 20-90% for various fruits such as blueberries, almonds, raspberries, and kiwifruit—but also addresses the decline in bee populations. By focusing on the health and efficiency of bees, Beeflow aims to maintain the security of plant ecosystems and support sustainable agriculture practices.

QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

JointechLabs, Inc. is a company that specializes in point-of-care regenerative medicine therapies, headquartered in Brandon, Florida. The organization develops innovative medical devices, including the MiniTC® for the United States and the Mini-Stem System® for international markets. These devices facilitate the processing of autologous body fat, enabling safe and efficient use in non-surgical orthopedic and aesthetic procedures within medical offices. By providing a closed-loop disposable system for human tissue processing, JointechLabs simplifies the creation of high-quality injectable fat grafts and fat-derived stem cells, making individualized cell and tissue-based therapies more accessible and cost-effective for hospitals and clinics. Additionally, the company is expanding its product pipeline to include biologic drugs and 3D bioprinted products aimed at orthopedic, wound healing, and plastic and reconstructive surgery applications.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Ria Health is an online platform that provides telehealth services for individuals looking to improve their relationship with alcohol. It offers personalized treatment plans that include medication-assisted treatment options and behavioral therapies, all supported by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability in their recovery journey. Ria Health features a mobile app that grants users access to educational materials, support groups, and direct communication with care teams. This comprehensive approach aims to assist individuals in managing alcohol consumption and fostering healthier habits.

AvantGuard creats innovative solutions that manage surfaces and provide long-term protection against viruses, bacteria, and fungi/mold, in a variety of applications.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Wayfinder Biosciences is a biotechnology company based in Seattle, WA, focused on developing orally available small molecule drugs that target RNA to address key disease areas such as oncology and neurodegenerative disorders. Established in 2021, the company employs a proprietary platform that integrates advanced screening technologies and computational methods to efficiently discover potent and selective RNA-targeting molecules. By leveraging high-throughput screening combined with machine learning and unique datasets, Wayfinder aims to enable the development of drugs for traditionally inaccessible targets, thus addressing significant unmet medical needs in genetic diseases, cancer, and other conditions.

Proteinea is a biotechnology company that specializes in developing biotherapeutics by utilizing advanced protein engineering techniques. The company has created a platform that employs proprietary artificial intelligence models and computational tools to design next-generation antibodies with enhanced efficacy, safety, and convenience. By integrating novel deep-learning models with smart experimental throughput, Proteinea aims to streamline the process of biologics design for antibody medicines. This innovative approach allows clients to evaluate the efficacy, yield, safety, and pharmacological properties of their products more effectively, ultimately leading to smarter and faster development of therapeutic solutions.